NCT02954887 - Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 12, 2017

Primary Completion Date

June 13, 2019

Study Completion Date

June 13, 2019

Conditions

Infantile Spasms

Interventions

DRUG

GWP42003-P

Clear, colorless to yellow solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.

Trial Locations (7)

22601

Valley Health Clinical Research, Winchester

27157

Wake Forest Baptist Medical Center, Winston-Salem

38103

Le Bonheur Children's Hospital, Memphis

43205

Nationwide Children's Hospital, Columbus

72202

Arkansas Children's Hospital, Little Rock

Unknown

Uniwersyteckie Centrum Kliniczne, Gdansk

Centrum Medyczne POMOC, Lodz